[PATHOPHYSIOLOGY OF CARDIORENAL SYNDROME]

Area of Science:

• Cardiology
• Nephrology
• Pathophysiology

Background:

• The traditional understanding of cardiorenal syndromes (SCR) focused on left ventricular systolic dysfunction reducing renal blood flow.
• Recent research challenges this view, suggesting other hemodynamic factors are more significant in SCR pathophysiology.
• Emerging evidence points to a multifactorial etiology involving various interconnected systems.

Purpose of the Study:

• To provide an updated overview of the complex pathophysiology of cardiorenal syndromes (SCR).
• To discuss the evolving understanding of hemodynamic, neurohormonal, and other contributing factors in SCR.
• To identify potential new therapeutic targets based on recent discoveries in SCR mechanisms.

Main Methods:

• Review of current literature on cardiorenal syndrome pathophysiology.
• Analysis of recent findings regarding hemodynamic alterations, particularly increased venous pressure.
• Synthesis of information on neurohormonal pathways, endothelial dysfunction, and associated conditions.

Main Results:

• Increased venous pressure, indicated by elevated abdominal pressure, is increasingly recognized as a key hemodynamic factor in SCR.
• Neurohormonal mechanisms involving the autonomic nervous system, renin-angiotensin-aldosterone system, arginine vasopressin, adenosine, and inflammatory mediators play a crucial role.
• Abnormal endothelial function, contributing to reduced shear stress, exacerbates SCR.
• Atherosclerosis, proteinuria, anemia, altered iron metabolism, nutritional status, vitamin D deficiency, and FGF23 changes are identified as significant contributing factors.

Conclusions:

• The pathophysiology of cardiorenal syndromes is more complex than previously thought, involving multiple interacting mechanisms.
• Increased venous pressure and neurohormonal dysregulation are critical components of SCR.
• Factors like endothelial dysfunction, atherosclerosis, and metabolic disturbances offer potential avenues for novel therapeutic strategies in managing SCR.